A5054677591- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Genetic Neurodegenerative Diseases
- Restless Legs Syndrome Research
- Neurological diseases and metabolism
- Sleep and Wakefulness Research
- Autism Spectrum Disorder Research
- Nuclear Receptors and Signaling
- Parkinson's Disease and Spinal Disorders
- Transcranial Magnetic Stimulation Studies
- Alzheimer's disease research and treatments
- Mitochondrial Function and Pathology
- Advanced Neuroimaging Techniques and Applications
- Attention Deficit Hyperactivity Disorder
- Dysphagia Assessment and Management
- Ginkgo biloba and Cashew Applications
- Cerebral Palsy and Movement Disorders
- Nerve injury and regeneration
- Sleep and related disorders
- Olfactory and Sensory Function Studies
- Neurological and metabolic disorders
- Child Nutrition and Feeding Issues
- Voice and Speech Disorders
- Cardiovascular Syncope and Autonomic Disorders
Innsbruck Medical University
2016-2025
Universität Innsbruck
2016-2025
Medical University of Vienna
2007-2024
John Wiley & Sons (United States)
2018-2024
Heinrich Heine University Düsseldorf
2022
Düsseldorf University Hospital
2022
Hertie Institute for Clinical Brain Research
2006-2022
Roche (Switzerland)
2022
Biomedical Research Networking Center on Neurodegenerative Diseases
2015-2020
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015-2020
We present a clinimetric assessment of the Movement Disorder Society (MDS)-sponsored revision Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UDPRS Task Force revised and expanded UPDRS using recommendations from published critique. MDS-UPDRS has four parts, namely, I: Non-motor Experiences Daily Living; II: Motor III: Examination; IV: Complications. Twenty questions are completed by patient/caregiver. Item-specific instructions an appendix complementary additional scales...
<b>Background: </b> A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies advanced the field, requiring a fresh evaluation of diagnostic criteria. We held second 2007 present results here. <b>Methods: Experts aspects MSA were invited to participate 2-day conference. Participants divided into five groups, consisting specialists parkinsonian,...
Neurostimulation of the subthalamic nucleus reduces levodopa-related motor complications in advanced Parkinson's disease. We compared this treatment plus medication with medical management.In randomized-pairs trial, we enrolled 156 patients disease and severe symptoms. The primary end points were changes from baseline to six months quality life, as assessed by Disease Questionnaire (PDQ-39), severity symptoms without medication, according Unified Rating Scale, part III (UPDRS-III).Pairwise...
The Movement Disorder Society Task Force for Rating Scales Parkinson's disease (PD) prepared a critique of the Hoehn and Yahr scale (HY). Strengths HY include its wide utilization acceptance. Progressively higher stages correlate with neuroimaging studies dopaminergic loss, high correlations exist between some standardized scales motor impairment, disability, quality life. Weaknesses scale's mixing impairment disability non-linearity. Because is weighted heavily toward postural instability...
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity limited variant syndromes with presentations other than Richardson's syndrome. Objective: We aimed to provide an evidence- consensus-based revision clinical criteria PSP. Methods: searched PubMed, Cochrane, Medline, PSYCInfo databases articles English...
This article presents the revision process, major innovations, and clinimetric testing program for Movement Disorder Society (MDS)-sponsored of Unified Parkinson's Disease Rating Scale (UPDRS), known as MDS-UPDRS. The UPDRS is most widely used scale clinical study disease (PD). MDS previously organized a critique UPDRS, which cited many strengths, but recommended to accommodate new advances resolve problematic areas. An MDS-UPDRS committee prepared using recommendations published scale....
Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of dual cholinesterase inhibitor rivastigmine such patients.
Neurostimulation of the internal globus pallidus has been shown to be effective in reducing symptoms primary dystonia. We compared this surgical treatment with sham stimulation a randomized, controlled clinical trial.Forty patients segmental or generalized dystonia received an implanted device for deep-brain and were randomly assigned receive either neurostimulation 3 months. The end point was change from baseline months severity symptoms, according movement subscore on Burke-Fahn-Marsden...
A therapy that slows disease progression is the major unmet need in Parkinson's disease.In this double-blind trial, we examined possibility rasagiline has disease-modifying effects disease. total of 1176 subjects with untreated were randomly assigned to receive (at a dose either 1 mg or 2 per day) for 72 weeks (the early-start group) placebo 36 followed by delayed-start group). To determine positive result dose, treatment group had meet each three hierarchical end points primary analysis...
Abstract Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using 18 F‐dopa positron emission tomography (PET) suggested slower loss of striatal storage with compared levodopa. This prospective, 2‐year, randomized, double‐blind, multinational the rates dopamine‐terminal function de novo patients PET evidence early PD, randomized 1 to receive either or The primary outcome measure was reduction...
Depression is a common comorbid condition in Parkinson's disease (PD) and major contributor to poor quality of life disability. However, depression can be difficult assess patients with PD due overlapping symptoms difficulties the assessment cognitively impaired patients. As several rating scales have been used (dPD), Movement Disorder Society commissioned task force their clinimetric properties make clinical recommendations regarding use. A systematic literature review was conducted explore...